Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

2.6%

1 terminated/withdrawn out of 38 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

24%

9 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

15 recruiting

Enrollment Performance

Analytics

Phase 2

8(33.3%)

N/A

6(25.0%)

Phase 4

5(20.8%)

Phase 3

4(16.7%)

Early Phase 1

1(4.2%)

24Total

Phase 2(8)

N/A(6)

Phase 4(5)

Phase 3(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials

NCT05738642Not ApplicableCompleted

Efficacy and Safety of Early Use PCC in Severe Trauma

Role: collaborator

NCT07507825Phase 2Not Yet Recruiting

Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)

Role: collaborator

NCT07395596Phase 4Recruiting

Remimazolam for Bronchoscopy in High-Risk Patients

Role: collaborator

NCT07413809Phase 3Recruiting

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

Role: collaborator

NCT05722405Phase 4Recruiting

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Role: collaborator

NCT07306260Not ApplicableNot Yet Recruiting

Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2

Role: collaborator

NCT07306247Not ApplicableNot Yet Recruiting

Multicenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection

Role: collaborator

NCT06520163Phase 3Recruiting

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Role: collaborator

NCT07088757Phase 4Recruiting

Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

Role: collaborator

NCT07203248Not Yet Recruiting

Chinese Real-world Study of Treatment of Vestibular Migraine

Role: collaborator

NCT04669496Phase 2Active Not Recruiting

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Role: collaborator

NCT07078500Phase 2Recruiting

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT04939922Recruiting

China Headache and Vertigo Registry Study

Role: collaborator

NCT06953752Not ApplicableRecruiting

Effects of Music During Atrial Fibrillation Ablation Under Conscious Sedation

Role: lead

NCT07022223Phase 2Recruiting

Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

Role: collaborator

NCT04624295Phase 4Recruiting

Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)

Role: collaborator

NCT05418218Recruiting

International Headache Registry Study

Role: collaborator

NCT06709144Phase 3Active Not Recruiting

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

Role: collaborator

NCT06699459Phase 2Not Yet Recruiting

Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC

Role: collaborator

NCT06644027Not ApplicableNot Yet Recruiting

Prevention of Incontinence-associated Dermatitis and Maintenance of Local Skin Microclimate：A Multicenter Study

Role: collaborator